Another Canadian Province Switches To Biosimilars

Prince Edward Island Is The Latest Jurisdiction In Canada To Introduce A Switching Initiative

Prince Edward Island has become the 11th Canadian province or territory to introduce a biosimilar switching scheme, covering eight different originator products.

Flag of Prince Edward Island on flagpole
Prince Edward Island has introduced a biosimilar switching scheme • Source: Shutterstock

Momentum is continuing for biosimilars switching programs in Canada, with Prince Edward Island – the smallest Canadian province in terms of geographical size and population – becoming the 11th Canadian province or territory to introduce such an initiative.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By 

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By 

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.